CN101595106B - 作为治疗药物的取代的γ内酰胺 - Google Patents

作为治疗药物的取代的γ内酰胺 Download PDF

Info

Publication number
CN101595106B
CN101595106B CN200880003507.5A CN200880003507A CN101595106B CN 101595106 B CN101595106 B CN 101595106B CN 200880003507 A CN200880003507 A CN 200880003507A CN 101595106 B CN101595106 B CN 101595106B
Authority
CN
China
Prior art keywords
another embodiment
phenyl
compound
och
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200880003507.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN101595106A (zh
Inventor
D·W·奥尔德
W·B·艾姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CN101595106A publication Critical patent/CN101595106A/zh
Application granted granted Critical
Publication of CN101595106B publication Critical patent/CN101595106B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CN200880003507.5A 2007-01-31 2008-01-29 作为治疗药物的取代的γ内酰胺 Expired - Fee Related CN101595106B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88741507P 2007-01-31 2007-01-31
US60/887,415 2007-01-31
PCT/US2008/052318 WO2008094912A2 (en) 2007-01-31 2008-01-29 Substituted gamma lactams as therapeutic agents

Publications (2)

Publication Number Publication Date
CN101595106A CN101595106A (zh) 2009-12-02
CN101595106B true CN101595106B (zh) 2014-05-07

Family

ID=39639429

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880003507.5A Expired - Fee Related CN101595106B (zh) 2007-01-31 2008-01-29 作为治疗药物的取代的γ内酰胺

Country Status (11)

Country Link
US (1) US7960381B2 (enExample)
EP (1) EP2121672B1 (enExample)
JP (1) JP5566692B2 (enExample)
KR (1) KR101561706B1 (enExample)
CN (1) CN101595106B (enExample)
AU (1) AU2008210559B2 (enExample)
BR (1) BRPI0808377B8 (enExample)
CA (1) CA2676291C (enExample)
MX (1) MX2009008039A (enExample)
NZ (1) NZ578698A (enExample)
WO (1) WO2008094912A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377984B2 (en) * 2008-01-29 2013-02-19 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US7820661B2 (en) * 2008-04-24 2010-10-26 Allergan, Inc. Substituted gamma lactams as therapeutics agents
BRPI0910741A2 (pt) 2008-04-24 2015-09-29 Allergan Inc arilciclopentenos substituídos como agonistas de prostaglantina ep2
EP2291367A1 (en) * 2008-04-24 2011-03-09 Allergan, Inc. Substituted gamma lactams as therapeutic agents
KR20110017878A (ko) * 2008-05-09 2011-02-22 알러간, 인코포레이티드 치료학적인 치환된 티아졸리딘온, 옥사졸리딘온, 및 관련 화합물
EP2285775B1 (en) * 2008-05-20 2017-03-22 Allergan, Inc. Lactams and their use in the treatment of inter alia ocular hypertension or baldness

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1653046A (zh) * 2002-03-05 2005-08-10 小野药品工业株式会社 8－氮杂前列腺素衍生化合物以及包含该化合物作为活性成分的药物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004521954A (ja) * 2001-07-16 2004-07-22 エフ．ホフマン−ラ　ロシュ　アーゲー Ｅｐ４受容体作用薬としてのプロスタグランジン類似体
ES2246419T3 (es) * 2001-11-05 2006-02-16 Allergan, Inc. Analogos de omega-cicloalquil-17-heteroaril-prostaglandina e2 como agonistas del receptor ep-2.
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
AU2003237520B2 (en) * 2002-06-10 2009-01-08 Laboratoires Serono Sa Gamma lactams as prostaglandin agonists and use thereof
US7091231B2 (en) * 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
EP1856042B1 (en) * 2005-03-10 2012-06-27 Allergan, Inc. Substituted gamma lactams as therapeutic agents
AU2007226957B2 (en) * 2006-03-20 2013-08-15 Allergan, Inc. Substituted gamma lactams as prostaglandin EP2 agonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1653046A (zh) * 2002-03-05 2005-08-10 小野药品工业株式会社 8－氮杂前列腺素衍生化合物以及包含该化合物作为活性成分的药物

Also Published As

Publication number Publication date
EP2121672A2 (en) 2009-11-25
AU2008210559B2 (en) 2014-03-06
US7960381B2 (en) 2011-06-14
CA2676291C (en) 2017-11-28
EP2121672B1 (en) 2014-12-10
NZ578698A (en) 2012-04-27
WO2008094912A2 (en) 2008-08-07
WO2008094912A3 (en) 2008-10-09
MX2009008039A (es) 2009-08-18
JP5566692B2 (ja) 2014-08-06
KR101561706B1 (ko) 2015-10-19
BRPI0808377B1 (pt) 2020-01-21
US20100093729A1 (en) 2010-04-15
BRPI0808377B8 (pt) 2021-05-25
CA2676291A1 (en) 2008-08-07
JP2010516817A (ja) 2010-05-20
CN101595106A (zh) 2009-12-02
BRPI0808377A2 (pt) 2014-07-08
WO2008094912B1 (en) 2008-11-20
AU2008210559A1 (en) 2008-08-07
KR20090104905A (ko) 2009-10-06

Similar Documents

Publication Publication Date Title
CA2787782C (en) Therapeutic substituted chlorocyclopentanols
CN101868455B (zh) 治疗性的取代的内酰胺
CN101595106A (zh) 作为治疗药物的取代的γ内酰胺
CA2689293A1 (en) Prostaglandin prodrugs
BRPI0711461A2 (pt) compostos terapeuticos
AU2009209330B2 (en) Substituted gamma lactams as therapeutic agents
JP2011518834A (ja) 治療剤としての置換ガンマラクタム
JP5566696B2 (ja) 緑内障または上昇眼内圧の治療用ガンマ‐ラクタム類
BRPI0712500A2 (pt) compostos terapêuticos de pirrolidina
US8440819B2 (en) Therapeutic substituted beta-lactams
BRPI0806716A2 (pt) arilciclopentenos substituìdos como agentes terapêuticos
JP2011520811A (ja) 治療用の置換チアゾリジノン類、オキサゾリジノン類および関連化合物
JP2011510085A (ja) 緑内障治療におけるヒドラジン類
JP2011520807A (ja) 治療用置換ヒダントイン類および関連化合物
JP2011519937A (ja) 治療用ｎ‐アリールまたはｎ‐ヘテロアリールピラゾリジンおよびピラゾリジノン誘導体
CA2787946A1 (en) Therapeutically active cyclopentanes

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140507

Termination date: 20220129